A decision is expected in the fourth quarter of 2025.

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A Maryland man has filed a lawsuit against the manufacturers of Ozempic, alleging that his use of the drug led to him ...

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

PLAINSBORO, N.J., April 29, 2025 /PRNewswire/ -- Today, Novo Nordisk announced it is expanding ... We believe patients living with this chronic disease who want and need treatment under the ...

Credit: Novo Nordisk. Self-paying patients will now ... “We believe patients living with this chronic disease who want and need treatment under the care of a licensed health care professional ...